Brief: Biocartis Expands Collaboration Agreement With AstraZeneca

Biocartis NV

22/06/2022 06:18

June 22 (Reuters) - Biocartis Group NV  BCART.BR :
    * BIOCARTIS EXPANDS MASTER COLLABORATION AGREEMENT WITH
ASTRAZENECA
    * ANNOUNCES NEW AGREEMENT WITH ASTRAZENECA FOR DEVELOPMENT
AND
MARKETING OF A COMPANION DIAGNOSTIC TEST FOR TAGRISSO®
    * BIOCARTIS, ASTRAZENECA TO CO-LEAD DEVELOPMENT, APPLICABLE
PRE-MARKET NOTIFICATION OR APPROVAL OF IDYLLA™ EGFR CDX ASSAY
FOR PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC)
    * BIOCARTIS TO ALSO SEEK TO VALIDATE USE OF LESS INVASIVE
CYTOLOGY
SAMPLES SUCH AS FINE NEEDLE ASPIRATES(3) FOR USE WITH IDYLLA™
EGFR CDX ASSAY, TO EXPAND PATIENT TESTING ACCESS
    * NEW PROJECT EXPANDS EXISTING MASTER COLLABORATION
AGREEMENT
ANNOUNCED IN JANUARY 2020 BETWEEN BIOCARTIS AND ASTRAZENECA
    * NEWLY SIGNED AGREEMENT INCLUDES INVESTIGATIONAL USE OF
IDYLLA™
EGFR CDX ASSAY TO ENROLL PATIENTS IN CLINICAL TRIALS AT
ASTRAZENECA

Source text for Eikon:  ID:nGNE6NWkTZ 
Further company coverage:  BCART.BR 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))